Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical Study

$CSII
Medical/Dental Instruments
Health Care
Get the next $CSII alert in real time by email

KAIZEN to assess safety and efficacy of peripheral orbital atherectomy to secure regulatory approval in Japan

Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company has initiated the KAIZEN clinical study of its Diamondback 360© Peripheral Orbital Atherectomy System (OAS) for the treatment of calcified plaque in patients with peripheral artery disease (PAD). The study is intended to support regulatory approval in Japan.

The first KAIZEN patient was enrolled by Tatsuya Nakama, M.D., Vice Director, Department of Cardiology, Tokyo Bay Urayasu Ichikawa Medical Center.

Dr. Nakama said, "I felt that the Diamondback 360© Peripheral OAS offered both effective treatment and ease of use. I was able to observe significant vessel compliance change, which permitted satisfactory balloon expansion at low pressure. Additionally, I felt that minimal distal embolism compared to other devices throughout the procedure was greatly comforting. I look forward to further evaluation of the device, but believe it will be seen as a highly welcomed tool in the battle against calcified vessels."

The Diamondback 360© Peripheral OAS is a minimally invasive, single-use, catheter-based device that is uniquely designed to differentiate between hard, diseased plaque and healthy, compliant arterial tissue. The OAS orbiting crown reduces and modifies calcified plaque while preserving the healthy vessel wall in order to restore blood flow.2,3,4

KAIZEN is a prospective, single-arm, multi-center study led by Hiroyoshi Yokoi, M.D., Interventional Cardiologist, Director of the Cardiovascular Medicine Center and Director, Fukuoka Sanno Hospital. The study is designed to evaluate the safety and efficacy of CSI's Diamondback 360© Peripheral OAS in the treatment of de novo symptomatic calcified occlusive atherosclerotic lesions in the superficial femoral artery and/or popliteal artery. OAS has demonstrated safety and efficacy in the U.S. population and this study is designed to confirm this in Japan. The study is expected to enroll up to 100 subjects at up to 12 study sites.

Dr. Yokoi said, "Severely calcified peripheral vessels continue to be a significant challenge for both patient and caregiver, and the need for new treatment devices is greater than ever. I believe the Diamondback 360© Peripheral OAS has great potential for this underserved patient population, and I look forward to evaluating it in Japan. In addition, the high use of imaging by practitioners in Japan will provide greater insight into lesion morphology, and I am confident that this will also help us optimize treatment and safety using OAS."

PAD is due to accumulation of plaque in the peripheral arteries (atherosclerosis). PAD complexity increases as atherosclerotic plaques become more calcified.1 Numerous endovascular treatments are available, such as balloons and stents to restore blood flow in blocked arteries. However, calcified lesions are more difficult to treat during these procedures, leading to decreased balloon and stent success and higher procedural complication rates.1

Scott R. Ward, CSI's Chairman, President and Chief Executive Officer, said, "We look forward to completing KAIZEN and working with the investigators and regulators so that we may offer peripheral OAS therapy to physicians in Japan."

About Peripheral Artery Disease (PAD)

An estimated eight to 10 million Japanese suffer from PAD, which is caused by the accumulation of plaque in peripheral arteries reducing blood flow. Symptoms include leg pain when walking or at rest. Left untreated, PAD can lead to severe pain, immobility, non-healing wounds and eventually limb amputation. With risk factors such as diabetes and obesity on the rise, the prevalence of PAD is growing at double-digit rates.

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. For more information, visit www.csi360.com and follow us on LinkedIn and Twitter.

Safe Harbor

Certain statements in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this press release regarding the KAIZEN study, regulatory approval of peripheral OAS in Japan, and the commercial introduction of peripheral OAS in Japan, are forward-looking statements. These statements involve risks and uncertainties that could cause results to differ materially from those projected, including, but not limited to, the potential for unanticipated delays in enrolling medical centers and patients for the KAIZEN study; the effectiveness of peripheral OAS in the study; actual clinical results; regulatory developments, clearances and approvals; approval of our products for distribution in Japan; approval of products for reimbursement and the level of reimbursement in Japan; general economic conditions; and other factors detailed from time to time in CSI's SEC reports, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. CSI encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this release. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, CSI's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this release. The forward-looking statements made in this release are made only as of the date of this release, and CSI undertakes no obligation to update them to reflect subsequent events or circumstances.

CSI® and Diamondback 360® are trademarks of Cardiovascular Systems, Inc.

Product Disclosure:

Peripheral Products

The Stealth 360® PAD System and Diamondback 360® PAD System are percutaneous orbital atherectomy systems indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and stenotic material from artificial arteriovenous dialysis fistulae. The systems are contraindicated for use in coronary arteries, bypass grafts, stents or where thrombus or dissections are present. Although the incidence of adverse events is rare, potential events that can occur with atherectomy include: pain, hypotension, CVA/TIA, death, dissection, perforation, distal embolization, thrombus formation, hematuria, abrupt or acute vessel closure, or arterial spasm. See the instructions for use for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information call CSI at 1-877-274-0901 and/or consult CSI's website at www.csi360.com.

This system is not commercially available Japan.

  1. Rocha Singh,K.J.,Zeller,T.& Jaff, M.R. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv 83, E212-220,doi:10.1002/ccd.25387(2014).
  2. Safian, R. D. et al. Orbital atherectomy for infrapopliteal disease: device concept and outcome data for the OASIS trial. Catheter CardiovascInterv73,406-412,doi:10.1002/ccd.21898(2009).
  3. Babaev, A. et al. Orbital Atherectomy Plaque Modification Assessment of the Femoropopliteal Artery Via Intravascular Ultrasound (TRUTH Study).Vasc Endovascular Surg 49, 188-194,doi:10.1177/1538574415607361(2015).
  4. Adams, G. L., Khanna, P. K., Staniloae, C. S.,Abraham, J. P. & Sparrow, E. M. Optimal techniques with the Diamondback 360 degrees System achieve effective results for the treatment of peripheral arterial disease. J Cardiovasc Transl Res 4, 220-229,doi:10.1007/s12265-010-9255-x(2011).

 

Get the next $CSII alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CSII

DatePrice TargetRatingAnalyst
12/21/2022$15.00Equal Weight
Barclays
12/14/2022$25.00Buy
Lake Street
3/2/2022$22.00Underperform
BofA Securities
2/4/2022$25.00 → $20.00Outperform
SVB Leerink
11/17/2021Buy → Hold
Needham
11/10/2021Buy → Neutral
Guggenheim
11/10/2021$45.00 → $40.00Outperform
SVB Leerink
9/23/2021$50.00 → $49.00Buy
Needham
More analyst ratings

$CSII
Press Releases

Fastest customizable press release news feed in the world

See more
  • Cytek Biosciences Set to Join S&P SmallCap 600

    NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector May 1, 2023 S&P SmallCap 600 Addition Cytek Biosciences CTKB Health Care S&P SmallCap 600 Deletion Cardiovascular Systems CSII Health C

    $ABT
    $CSII
    $CTKB
    $SPGI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Laboratory Analytical Instruments
  • Cardiovascular Systems, Inc. Completes Enrollment of ECLIPSE Clinical Trial

    Largest randomized coronary atherectomy trial ever conducted Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today the company completed the enrollment of its 2,000 patient ECLIPSE coronary trial. ECLIPSE is a prospective, multi-center, randomized clinical trial of approximately 2,000 subjects with severely calcified coronary lesions in the United States. Half of the participants received orbital atherectomy prior to drug-eluting stent implantation, while the other half received conventional angioplasty, including speci

    $CSII
    Medical/Dental Instruments
    Health Care
  • Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results

    Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin

    $ABT
    $CSII
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

$CSII
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CSII
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CSII
SEC Filings

See more

$CSII
Leadership Updates

Live Leadership Updates

See more
  • Big Sky Biomedical Appoints Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director

    MINNEAPOLIS, March 7, 2022 /PRNewswire-PRWeb/ -- Big Sky Biomedical, a leading-edge medical device and health technology incubator, announced today that it has appointed Ryan Egeland, M.D., Ph.D., M.B.A., as Managing Director. "Big Sky Biomedical was founded to enhance early-stage innovation and development in some of the fastest growing segments of healthcare, including neurovascular, structural heart, and regenerative medicine," said Dr. Egeland. "I'm extremely excited to apply my scientific, medical, and commercial experience to our portfolio companies in a much broader and deeper capacity. Alongside our exceptional teams of engineers, scientists, operators, and physician partners, I loo

    $CSII
    $MDT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Cardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D., as Chief Medical Officer

    Cardiovascular Systems, Inc. (CSI) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary vascular disease, today announced that it has appointed Jeffery W. Chambers, M.D., as Chief Medical Officer. "CSI is developing an exciting product pipeline that targets some of the fastest growing segments of interventional cardiology," said Scott Ward, Chairman, President and Chief Executive Officer. "Jeff brings contemporary interventional cardiology practice and extensive clinical research experience to CSI as we seek to expand our product offering beyond orbital atherectomy. We believe Jeff brings valuable per

    $CSII
    Medical/Dental Instruments
    Health Care
  • Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

    CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

    $CSII
    $MEI
    $CNMD
    Medical/Dental Instruments
    Health Care
    Electrical Products
    Technology

$CSII
Financials

Live finance-specific insights

See more
  • Cardiovascular Systems, Inc. Reports Fiscal 2023 Second Quarter Financial Results

    Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its second quarter, ended December 31, 2022. Second Quarter Financial Highlights CSI's fiscal 2023 second quarter revenues were $61.5 million, representing an increase of $2.3 million, or 3.9% compared to the second quarter last year. Gross profit margin was 70.0%. Selling, general and administrative expenses were $41.6 million, an increase of $1.2 million, or 3.1%. Research and development expenses increased 7.4% to $9.5 million due to the timin

    $ABT
    $CSII
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
  • Cardiovascular Systems, Inc. to Host Earnings Conference Call on February 9, 2023

    Cardiovascular Systems, Inc. (NASDAQ:CSII) plans to announce its operating results for the quarter ended December 31, 2022 before the market opens on Thursday, February 9, 2023, and will host a conference call at 9:00 a.m. ET that day to discuss those results. Click here to access the live webcast. A replay will be available later the same day. Click here to register for the conference call. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic pla

    $CSII
    Medical/Dental Instruments
    Health Care
  • Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results

    Conference Call Scheduled for Today, November 3, 2022, at 8:00 a.m. CT (9:00 a.m. ET)  Revenues of $59.7 million increased 2.2% compared to first quarter last year Management reiterates fiscal 23 revenue guidance of $255 million to $265 million, representing 8% to 12% growth Cardiovascular Systems, Inc. (CSI®) (NASDAQ:CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its first quarter, ended September 30, 2022. Executive Commentary – Scott Ward, Chairman, President and CEO "We are pleased with the state of our business and our perfor

    $CSII
    Medical/Dental Instruments
    Health Care

$CSII
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more